It is intended to provide an uracil derivative represented by the following general formula (I): (I) wherein X represents a group selected from among NHCO, NHCH.sub.2, CO, CONH and CH.sub.2NH; R.sup.1 represents hydrogen or optionally substituted C.sub.1-6 alkyl; R.sup.2 represents a group of the following general formula (II) or (III): (II) (III) (wherein m is 0 or 1; n is an integer of from 1 to 3; Y represents OH or NH.sub.2; and a dotted line shows a binding position), provided that when R.sup.2 is a group of the general formula (III), X represents NHCO or NHCH.sub.2; R.sup.3 and R.sup.4 independently represent each hydrogen or C.sub.1-6 alkyl; and Ar represents phenyl substituted by C.sub.1-6 alkyl at the o- and m-positions, optionally substituted heteroaryl or a bicyclic aromatic group; its pharmaceutically acceptable salt, and a remedy containing the above uracil derivative or its pharmaceutically acceptable salt as the active ingredient for, in particular, allergic diseases relating to a type IV allergic reaction, i.e., a novel compound useful in treating diseases in which a type IV allergic reaction participates and a remedy for allergic diseases containing the same as the active ingredient.